Related Experiment Video
Updated: Jul 20, 2026
06:39
Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants
Published on: June 13, 2021
3.1K
Mangiferin Alleviates Postpartum Depression-Like Behaviors by Inhibiting MAPK Signaling in Microglia
Meichen Yan1, Xuena Bo1, Xinchao Zhang1
1Center on Translational Neuroscience, College of Life and Environmental Science, Minzu University of China, Beijing, China.
Frontiers in Pharmacology
|June 20, 2022
Summary
Mangiferin (MGF) can alleviate postpartum depression (PPD)-like behaviors by reducing neuroinflammation and microglial activation. This study explores MGF as a potential therapeutic for PPD.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Postpartum depression (PPD) is linked to hormonal changes and neuroinflammation.
- Mangiferin (MGF) has anti-inflammatory properties, but its role in PPD is unclear.
Purpose of the Study:
- To investigate the therapeutic potential of Mangiferin (MGF) in a mouse model of postpartum depression (PPD).
- To elucidate the underlying mechanisms of MGF's action in PPD.
Main Methods:
- A hormone-simulated pregnancy PPD mouse model was established.
- MGF was administered to assess its effects on PPD-like behaviors.
- Microglial activation, neuroinflammation, and MAPK signaling were analyzed.
Main Results:
- MGF administration significantly reduced PPD-like behaviors in the mouse model.
- MGF inhibited microglial activation and suppressed neuroinflammation.
- MGF treatment downregulated mitogen-activated protein kinase (MAPK) signaling.
Conclusions:
- Mangiferin demonstrates therapeutic potential for postpartum depression.
- MGF's efficacy is mediated through the inhibition of microglial activation and neuroinflammation.
- MGF may offer a novel therapeutic strategy for PPD treatment.
